LONDON & AUSTIN, Texas--(BUSINESS WIRE)--Gendux AB and Introgen Therapeutics, Inc. (NASDAQ:INGN) announce today that Introgen has been certified with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) that its facilities and production processes are compliant with European Good Manufacturing Practices for the manufacture of ADVEXIN p53 therapy. This is an important milestone for ADVEXIN’s progress to licensure in the European Union. ADVEXIN is being developed in Europe and the United States for a variety of somatic and inherited cancer indications.